Rhythm Pharmaceuticals Announces Upcoming Financial Control Deficiencies
Company Announcements

Rhythm Pharmaceuticals Announces Upcoming Financial Control Deficiencies

Rhythm Pharmaceuticals Inc (RYTM) has released an update.

We expect to disclose a significant deficiency in our financial reporting controls in our upcoming annual report, particularly concerning IT general controls surrounding user access and program changes. These weaknesses may affect other related controls and the integrity of data from our key IT systems. While our external auditors have yet to finalize their audit, our management is working proactively with the Audit Committee and external advisors to address and rectify these issues.

For further insights into RYTM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyRhythm Pharmaceuticals price target raised to $80 from $53 at Wells Fargo
TheFlyRhythm Pharmaceuticals price target raised to $69 from $64 at H.C. Wainwright
TipRanks Auto-Generated NewsdeskRhythm Pharmaceuticals’ Common Stock Faces Risks from Convertible Preferred Stock Supremacy
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App